Appili has assembled a leadership team with expertise in all facets of drug development, from bench to bedside.

Appili’s management team is comprised of experts in drug development, infectious disease, business development, and commercialization. Our collective experience spans large pharma to emerging biopharmaceutical firms.

 
 
 
 

Armand Balboni, MD, PhD

Chief Executive Officer

Armand Balboni's career includes medical research and drug development experience in civilian, academic and military organizations, most recently as a partner at Bloom Burton & Co. where he was the firms senior advisor for regulatory and medical affairs. As an active duty military officer, Dr. Balboni served as a staff officer at the U.S. Army Research Institute of Infectious Diseases (USAMRIID). He completed a military staff fellowship at the U.S. Food and Drug Administration and went on to serve as the deputy director of clinical and regulatory affairs for the U.S. Army. Armand completed his doctoral work in the MD/PhD program at the Icahn School of Medicine at Mount Sinai and earned his law degree at Brooklyn Law School.

Kimberly Stephens, CPA, CA

Chief Financial Officer

Kimberly Stephens is the Chief Financial Officer, who brings nearly 20 years of financial management experience at public and private companies to her role at Appili. Most recently Ms. Stephens served as CFO of IMV Inc. (formerly Immunovaccine) (Nasdaq: IMV; TSX: IMV), where she raised more than $40 million in equity financing and government grants. She was instrumental in IMV’s graduation from the TSX Venture Exchange to the TSX and listing on the OTCQX in the USA. Ms. Stephens began her career as an audit manager at PwC and has extensive experience across multiple industries in addition to the life science sector, including financial services, software and oil and gas.

Myriam Triest, PhD

Senior Director, Product Development

Myriam Triest brings over 15 years of experience as a drug development professional and chemist to her role as Director of Manufacturing and Pharmaceutical Development. She manages the chemical, regulatory, and quality aspects of Appili’s drug development pipeline. In her previous role as Director of Product Development at Locemia Solutions (Montreal), Dr. Triest supported the development of a combination drug candidate from discovery through a successful phase 3 clinical program that was ultimately licensed to Eli Lilly for $150M USD upfront plus milestones. In addition, she brings to Appili experience as a vice president of a clinical research organization with a wide range of drug development programs, including small molecules, peptides, and medical devices. She earned her PhD from Katholieke Universiteit Leuven, Belgium and completed her post-doctorate fellowship at Université de Montréal.

Stéphane Paquette, PhD

Director, Business Development

 

As Director, Business Development, Stéphane Paquette directs evaluation and licensing activities for Appili, as well as key stakeholder and partner management.  Dr. Paquette brings extensive infectious disease and R&D experience to his role at Appili, with over 10 years in industry and leading academic institutions.  Prior to joining Appili, Dr. Paquette was a researcher at the University Health Network / University of Toronto studying emerging viral pathogens, immune responses to infection and vaccination, and novel antiviral compounds.  Previously, Dr. Paquette was Associate Scientist at Abbott Point of Care where he conducted exploratory R&D on novel diagnostic assays.  He is author on 14 peer-reviewed publications in the fields of infectious disease and biochemistry, and holds a PhD from the University of Toronto with a BSc in Microbiology & Immunology from McGill University.